{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:16:48Z","timestamp":1760059008068,"version":"build-2065373602"},"reference-count":21,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Germany"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>This study aims to identify parameters predicting COVID-19 inflammation score (CIS) response and survival probability in critically ill patients with hyperinflammation treated with the Janus kinase (JAK) 1\/2 inhibitor ruxolitinib. This is a single arm, non-randomized, open-label, phase-II study for frontline treatment in adults in the intensive care unit (ICU). Ninety-two critically ill COVID-19 patients with CIS \u2265 10 were treated in the RuxCoFlam trial (NCT04338958) with ruxolitinib between April 2020 and June 2021. Median ICU treatment duration was 15 days (range, 2\u201373). Out of 81 evaluable patients, 62 (77%) showed CIS reduction \u2265 25% on day 7 (CIS response). In multiple logistic regression analyses, higher CIS on day 0 (odds ratio (OR), 1.56; 95% confidence interval (CI), 1.01\u20132.41; p = 0.046) and male gender (OR, 4.76; 95% CI, 1.22\u201316.67; p = 0.024) were significantly associated with CIS response. Sixty-day survival probability was higher in CIS-responders compared to non-responders (74% vs. 32%; p &lt; 0.001). Multiple Cox regression analysis revealed younger age (10-year difference) (hazard ratio (HR), 0.65; 95% CI, 0.46\u20130.91; p = 0.012) and CIS response (HR, 0.19; 95% CI, 0.08\u20130.45; p &lt; 0.001) as significant parameters for survival probability. In conclusion, reduced risk of death in CIS-responders underlines the usefulness of CIS for the assessment of hyperinflammatory disorders, such as COVID-19, under JAK1\/2 inhibitor therapy.<\/jats:p>","DOI":"10.3390\/life15050781","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:59:29Z","timestamp":1747195169000},"page":"781","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Impact of COVID-19 Inflammation Score Response: A Sub-Group Analysis on Critically Ill Patients of the RuxCoFlam Trial"],"prefix":"10.3390","volume":"15","author":[{"given":"Manfred","family":"Weiss","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr An\u00e4sthesiologie und Intensivmedizin, Universit\u00e4tsklinikum Ulm, 89081 Ulm, Germany"},{"name":"Klinik f\u00fcr An\u00e4sthesiologie und Operative Intensivmedizin, Universit\u00e4tsklinikum Augsburg, 86156 Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Hammersen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, H\u00e4matologie und Internistische Onkologie, Universit\u00e4tsklinikum Jena, 07743 Jena, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Rudolphi","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr An\u00e4sthesiologie und Intensivmedizin, Universit\u00e4tsklinikum Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabell","family":"Formann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr An\u00e4sthesiologie und Intensivmedizin, Universit\u00e4tsklinikum Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-5575","authenticated-orcid":false,"given":"Karl","family":"Tr\u00e4ger","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr An\u00e4sthesiologie und Intensivmedizin, Universit\u00e4tsklinikum Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank G.","family":"R\u00fccker","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, H\u00e4matologie, Onkologie, Palliativmedizin, Rheumatologie und Infektionskrankheiten, Universit\u00e4tsklinikum Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6669-3741","authenticated-orcid":false,"given":"Beate","family":"Gr\u00fcner","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, H\u00e4matologie, Onkologie, Palliativmedizin, Rheumatologie und Infektionskrankheiten, Universit\u00e4tsklinikum Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Allg\u00f6wer","sequence":"additional","affiliation":[{"name":"Institute of Epidemiology and Medical Biometry, Ulm University, 89075 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5430-899X","authenticated-orcid":false,"given":"Sebastian","family":"Birndt","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, H\u00e4matologie und Internistische Onkologie, Universit\u00e4tsklinikum Jena, 07743 Jena, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Fabisch","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, H\u00e4matologie und Internistische Onkologie, Universit\u00e4tsklinikum Jena, 07743 Jena, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, H\u00e4matologie und Internistische Onkologie, Universit\u00e4tsklinikum Jena, 07743 Jena, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, H\u00e4matologie, Onkologie, Palliativmedizin, Rheumatologie und Infektionskrankheiten, Universit\u00e4tsklinikum Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-7809","authenticated-orcid":false,"given":"Paul La","family":"Ros\u00e9e","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin II, H\u00e4matologie, Onkologie, Immunologie, Infektiologie und Palliativmedizin, Schwarzwald-Baar Klinikum, 78052 Villingen-Schwenningen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Stegelmann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, H\u00e4matologie, Onkologie, Palliativmedizin, Rheumatologie und Infektionskrankheiten, Universit\u00e4tsklinikum Ulm, 89081 Ulm, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cytogfr.2020.06.013","article-title":"The potential of JAK\/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19","volume":"54","year":"2020","journal-title":"Cytokine Growth Factor. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S2665-9913(22)00044-3","article-title":"Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Han","year":"2022","journal-title":"Lancet Rheumatol."},{"doi-asserted-by":"crossref","unstructured":"Botta, C., Indrieri, A., Garofalo, E., Biamonte, F., Bruni, A., Pasqua, P., Cesario, F., Costanzo, F.S., Longhini, F., and Mendicino, F. (2020). COVID-19: High-JAKing of the Inflammatory \u201cFlight\u201d by Ruxolitinib to Avoid the Cytokine Storm. Front. Oncol., 10.","key":"ref_3","DOI":"10.3389\/fonc.2020.599502"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1038\/s41375-020-0907-9","article-title":"Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)","volume":"34","author":"Neubauer","year":"2020","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1038\/s41375-021-01374-3","article-title":"The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)","volume":"35","author":"Neubauer","year":"2021","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/cts.12971","article-title":"Compassionate use of ruxolitinib in patients with SARS-CoV-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation","volume":"14","author":"Mortara","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3855\/jidc.15126","article-title":"Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: Clinical experience in a real-world setting","volume":"16","year":"2022","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/CCM.0000000000005682","article-title":"Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome","volume":"50","author":"Rein","year":"2022","journal-title":"Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41375-023-01979-w","article-title":"The JAK1\/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: The RuxCoFlam trial","volume":"37","author":"Hammersen","year":"2023","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"Bremer","year":"2020","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00277-023-05606-7","article-title":"A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: Ferritin\/platelet ratio","volume":"103","author":"Feng","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"ref_13","first-page":"e35423","article-title":"A Comparison of ICU Mortality Scoring Systems Applied to COVID-19","volume":"15","author":"Monk","year":"2023","journal-title":"Cureus"},{"doi-asserted-by":"crossref","unstructured":"Allyn, J., Ferdynus, C., Bohrer, M., Dalban, C., Valance, D., and Allou, N. (2016). Simplified Acute Physiology Score II as Predictor of Mortality in Intensive Care Units: A Decision Curve Analysis. PLoS ONE, 11.","key":"ref_14","DOI":"10.1371\/journal.pone.0164828"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study","volume":"270","author":"Lemeshow","year":"1993","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: Results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1007\/s11606-022-07511-7","article-title":"WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales","volume":"37","author":"Formiga","year":"2022","journal-title":"J. Gen. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Recovery Collaborative Group. Dexamethasone in Hospitalized Patients with COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41392-020-0191-1","article-title":"Immune response in COVID-19: Addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2","volume":"5","author":"Catanzaro","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e0876","DOI":"10.1097\/CCE.0000000000000876","article-title":"Intensive Care and Organ Support Related Mortality in Patients With COVID-19: A Systematic Review and Meta-Analysis","volume":"5","author":"Chandel","year":"2023","journal-title":"Crit. Care Explor."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0140-6736(22)01485-4","article-title":"Acute respiratory distress syndrome: Causes, pathophysiology, and phenotypes","volume":"400","author":"Bos","year":"2022","journal-title":"Lancet"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/5\/781\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:32:16Z","timestamp":1760031136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/5\/781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["life15050781"],"URL":"https:\/\/doi.org\/10.3390\/life15050781","relation":{},"ISSN":["2075-1729"],"issn-type":[{"type":"electronic","value":"2075-1729"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}